Hot Investor Mandate: Family Office Backed Investment Fund Seeks Life Science & Healthcare Companies in Australia and Beyond

15 Feb

An investment firm based in Australia is backed by one of Australia’s largest family offices. With its current fund, the firm will focus exclusively on life sciences & healthcare. The firm is focused on investing early-stage companies – while the firm has a focus on supporting the Australian ecosystem, the firm is open to global opportunities. 
 
The firm seeks to invest in therapeutics, diagnostics, and digital health companies and has no particular preference on specific types of technologies or disease area/indication. The firm prefers to see strong pre-clinical data, and is open to both pre-clinical and clinical projects. The firm does not invest in medical device companies at this time. 
 
The firm seeks to support companies with innovative technology, and is open to working with both first-time and experienced management teams. The firm can act as either lead or co-investor. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: US & Europe-Based Investment Group Allocates Up to $60M in Therapeutics, Devices, and Diagnostics Companies From Early Clinical Stage

15 Feb

An investment group located in the U.S. and Europe invests in early-stage life science companies from Seed to Series C. Typical check size can be up to $60M USD and varies depending on the fit. The firm makes investments to global companies acting as both a lead and co-investor. 
 
The firm is seeking to invest in biotech therapeutics, diagnostics, and medical devices. The firm is indication- and sub sector-agnostic and can fund companies from Phase I to Phase IV. 
 
The firm does not require to take a board seat, but rather seeks to run the clinical trial programs in exchange. The firm does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Family Office Invests in Technologies Addressing CNS Diseases and Disorders, Seeking Global Opportunities

15 Feb

A family office based in the US makes seed-stage and venture-stage equity investments; typical seed investments are of $250,000-500,000 initially with the potential for follow-on financing of up to $3 million. The firm is open to opportunities worldwide, and currently has portfolio companies in North America, Europe and Oceania. 
 
The firm funds early-stage companies across neurodegeneration, psychiatry and neurotech and also funds platform opportunities that raise the tide towards precision neuro. The firm invests across modalities. 
 
The firm invests in privately held companies and backs top scientists, who are pursuing breakthrough approaches rather than traditional. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Angel Group Seeks Early-Stage Investments in Medtech and Digital Health in Cardiology, Neurology, and More

15 Feb

An angel syndicate headquartered in Baltimore, Maryland. The group invests in device, diagnostics, and digital health companies globally. The group will invest as early as Seed rounds up to Series B. Typical check size falls between $250k-1M USD and prefers to co-invest. The firm will invest through equity or convertible notes. 
 
The firm invests in medical devices, digital health, and diagnostics. The firm does not invest in therapeutics. In terms of devices, the firm is open to all classes of devices. Current interest is in cardiology, structural heart, and neurology, but the firm is indication-agnostic. Although there is preference with earlier stages of development, the firm is stage-agnostic. 
 
The firm may take a board seat on a case-by-case basis. The firm requires companies to have at least one full time executive.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

LSN: Navigating the Path to Commercialization

8 Feb

By Dennis Ford, Founder and CEO of Life Science Nation, Creator of the RESI Conference Series

By helping startups develop compelling narratives for their fundraising campaigns and facilitating strategic partnerships through its extensive network, LSN plays a pivotal role in bridging the gap between academia and industry. Life Science Nation has developed a set of products and services that help startups navigate the fundraising chasm and find the right partners to aid them in their journey to commercialization. These challenges include:

  1. Navigating a New Field: Moving from academia to industry requires adapting to a new environment, understanding the rules, and building a professional network within the life science industry.
  2. Acquiring New Skillsets: Scientists-Entrepreneurs need to be open to learning or having staff that understand Sales, Marketing, and Business Development.
  3. Fundraising, Licensing, and Collaboration Trends: Early-stage life science companies face the challenge of staying informed about investment trends and securing funding, especially in the face of broader market challenges and uncertainties.
  4. Competition and Innovation: Rapid innovation and competition characterize the life science industry. To remain competitive, startups must stay abreast of the latest scientific advancements and disruptive technologies.
  5. Networking and Collaboration: Building a strong network of collaborators, investors, and partners is essential for early-stage life science companies. This includes understanding the dynamics of potential partnerships and effectively engaging with investors and partners.
  6. Market Dynamics and Global Expansion: Understanding market dynamics, both locally and globally, is crucial for startups. They must also develop a strategic plan for global expansion and navigate the complexities of launching and executing a global campaign and roadshow.
  7. Fostering Ongoing Partnerships: Successful partnerships require ongoing effort and a dedicated plan to maintain a consistent pipeline of partner meetings, even as these meetings ebb and flow over time.

Contrary to the popular assumption that science is enough, and focusing on that will lead to successful fundraising, making the transition from a scientist to an entrepreneur requires flexibility, passion, and a lot of drive and determination. A scientist has to transform and adapt, learning new skill sets and entering a new world, but those that want it can be extremely successful. Let us help you on that journey.

RESI-South-2024_02062024.

Register-now-button-new

RESI-SPAIN-1100

Confirmed Early-Stage Investors at RESI South in March 

8 Feb

By Faith Patenaude, Investor Research Analyst, LSN

Faith

Life Science Nation brings RESI to the south! The next RESI event is approaching on Monday, March 25th at The Whitley Atlanta Buckhead in Atlanta, Georgia. This event will be followed by two days of virtual partnering on March 26th and 27th. Monday will showcase our Investor Panels, esteemed Innovator’s Pitch Challenge, and Entrepreneur Workshops led by industry experts. Additionally, one-on-one partnering meetings will be available throughout all three days.

RESI South will feature over 250 investors within big pharma, venture capital funds, angel groups, family offices, and more. Investors invited and registered have been vetted by LSN’s investor research team to ensure those attending have active interest in early-stage life science investment opportunities. The team works to welcome relevant investors who share focus and interests aligned with those of the participating startups. Our Partnering Platform allows attendees to easily match with those of best fit. RESI presents an exceptional opportunity for early-stage startups, service providers, and investors to forge meaningful connections and expand their network within the life science sector.

Save up to $500 with our super early bird rate – ending tomorrow, Friday February 9th. Register to join us in Atlanta. 

Register-now-button-new

Below are a selected number of investors attending RESI South and more on the way:

CI-02082024

RESI-South-2024_02062024.

RESI-SPAIN-1100

RESI South Calling for Global Tech Hubs (Incubators, Accelerators, Universities, and More)

8 Feb

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

Early-stage life science startups that are affiliated with a tech hub (incubator, accelerator, university, non-profit, or regional/government agency) are eligible for up to $500 off to Life Science Nation’s RESI South, March 25 – 27th, in Atlanta, Georgia. To redeem a unique discount code, please reach out to Erika Wu at e.wu@lifesciencenation.com

Tech hubs are also eligible to save 50% off all sponsorship levels at RESI. This is a great opportunity to:

  1. Showcase startups’ technologies from your tech hub with the Innovator’s Pitch Challenge (IPC). Get a group rate for your startups!
  2. Host a workshop
  3. Get featured in LSN’s Next Phase and Tech Hub newsletters
  4. Showcase your tech hub’s services and value proposition at an exhibition booth

If your startups are not in fundraising mode, they can attend RESI South with an “Audience Access Pass” for $595, which gets access to view all in-person sessions (March 25th) including IPC pitch sessions, investor-led panels, workshops, exhibition, and a post-RESI networking reception.

Tech hubs currently registered for RESI South 2024 – Sign Up Here:

CTH-02082024

For any questions, please reach out to Erika Wu at e.wu@lifesciencenation.com

RESI-South-2024_02062024.

Register-now-button-new

RESI-SPAIN-1100

← Older Entries
Newer Entries →